SlideShare una empresa de Scribd logo
1 de 9
Descargar para leer sin conexión
February 01, 2011




                          A strong January; 5.4 percent excess return

Christian Blaabjerg       The Global Value Equity portfolio performed strongly in January with
Chief Equity Strategist   most contribution coming from our stock selection, driven by CNP
ctb@saxobank.com          Assurances and Almirall, with almost no help from our sector allocation.
+45 3977 4669

                             The Saxo Bank Global Value Equity Portfolio would have made
Peter Garnry                  excess return of 3.4 percent1 in the three months since the actual
Equity Strategist             inception in November 2010. In January, the portfolio returned 5.4
pg@saxobank.com               percent compared to the 0.01 percent for the MSCI World EUR index.
+45 3977 6786
                             Almirall, the Spanish pharmaceutical company, is, despite the 24
                              percent surge in January still a likely takeover candidate. The
                              extraordinary surge was driven by positive results from ATTAIN phase III
                              study. We have been saying for several months that Almirall is a takeover
                              candidate and in January Leerink Swann, a premier US investment bank
                              focused on healthcare, said AstraZeneca may consider buying Forrest
                              Laboratories or Almirall due to their attractive late-stage pipelines.

                             We are still very bullish on insurance stocks and believe our
                              exposure will drive outperformance over the next quarters. Among
                              insurance stocks we prefer CNP Assurances (still our most bullish individual
                              case), Tryg, Catlin Group and Scor - all trading at attractive levels compared
                              to their earnings power and prospects.




                          1. Past performance disclaimer
                          This publication refers to past performance. Past performance is not a reliable indicator of future performance.
                          Indications of past performance displayed on this publication will not necessarily be repeated in the future. No
                          representation is being made that any investment will or is likely to achieve profits or losses similar to those
                          achieved in the past or that significant losses will be avoided.

                          Statements contained on this publication that are not historical facts and which may be simulated past
                          performance or future performance data are based on current expectations, estimates, projections, opinions and
                          beliefs of the Saxo Bank Group. Such statements involve known and unknown risks, uncertainties and other
                          factors, and undue reliance should not be placed thereon. Additionally, this publication may contain 'forward-
                          looking statements'. Actual events or results or actual performance may differ materially from those reflected or
                          contemplated in such forward-looking statements.
February 01, 2011




Global Value Equity Portfolio – February 2011
           Changes to the February portfolio

           Only one stock placed on the bench despite a strong showing from many constituents
                 Helvetia Holding returned 3.46 percent in January and its relative valuation has benched the
                 stock for now. It helped the portfolio outperform as the benchmark only returned 0.01
                 percent in January. That was despite it being downgraded to “underperform” by Credit
                 Suisse.

           So, which stock is in for February?
                  CapitaCommerical Trust, a property trust company located in Singapore, is the new kid on
                  the block following a 4.7 percent decline in January adding to its relative valuation. The
                  company is currently valued at CAPE ratio (price over average three years earnings per
                  share) of 9.42 and a price-to-book of 1.2. During January UBS maintained its “buy”
                  recommendation on the stock and on current levels we think it could add 10-20 percent in
                  gains before losing its relative valuation attractiveness.

           Our February portfolio is comprised of the following stocks:




                                                                                                               2
February 01, 2011




The portfolio is still highly overweight financials stocks.
      Financials, particularly insurance stocks, are still trading at attractive levels relative to their
      earnings power over a normal economic cycle and we expect our insurance stocks to
      perform well over the next quarter.




The portfolio’s currency exposure is primarily in EUR, GBP and HKD (75 percent).
      The main currency exposure is unchanged from last month with high concentration in EUR,
      GBP and HKD. As Helvetia Holding left our portfolio and CapitaCommerical Trust replaced it,
      we changed a minor five percent exposure from CHF to SGD.




                                                                                                        3
February 01, 2011




Global Value Equity Portfolio – January 2011
          In January the portfolio returned 5.42 percent compared to 0.01 percent for MSCI World
          EUR index. Since inception in November 2010 the portfolio is up 11.9 percent compared to 8.5
          percent for the MSCI World EUR index which corresponds to a 3.4 percentage point outperformance
          in three months.

          Which stocks were strong performers in the portfolio?
                 Almirall, the Spanish pharmaceutical company, surged 24.0 percent in January following
                 positive results from its‟ ATTAIN phase III study which the company develops in
                 cooperation with Forrest Laboratories. The company is still valued attractively compared to
                 its earnings power and late-stage pipeline making it an obvious takeover candidate for
                 another pharmaceutical company with trouble in its pipeline.
                 CNP Assurances, the French life insurance company, rose 19.2 percent in January on no
                 significant public announcement but was raised to “outperform” and “overweight” from
                 Credit Suisse and HSBC respectively. Their target price range is around EUR 19.50-20
                 which is a 21.1-24.2 percent premium from January‟s closing price.
                 Kowloon Development, the Hong Kong based developer of properties, put on 17.8 percent
                 in January on increased risk appetite for Asian real estate exposure.

          Which stocks held the portfolio back?
                Ten Network Holdings, the Australian operator of commercial television stations, declined
                5.8 percent in January on no public news or events; actually it was upgraded by RBS. We
                see minor upside in this stock compared to the rest of the portfolio.
                Amlin, the U.K. insurance and reinsurance company, declined 4.2 percent in January due to
                a profit warning following a revision of the estimated costs from the earthquake in New
                Zealand; the costs doubled from first anticipated by management.

          January portfolio performance




          Performance attribution




                                                                                                           4
February 01, 2011




Portfolio basics
           Value creates excess risk-adjusted return. This equity portfolio is based on classical deep value
           criteria mixed with a quality indicator based on a Piotroski score. Our portfolio would have produced
           excess risk-adjusted return in the back testing period of 10.3%; the annual return was 10.7% p.a.
           compared to 0.4% p.a. return for our benchmark, the MSCI World Index EUR.

           Global portfolio without constrains. Our equity portfolio has no constraints in terms of exposure
           restrictions towards geography or sectors. The portfolio seeks to exploit deep value opportunities
           wherever they are located in the world. We have found during back-testing that the additional risk
           taken by this approach is sufficiently offset by the extra return received.

           Equal weighted portfolio. The portfolio is based on an equal weighted approach and the monthly
           return is calculated accordingly on these weights.

           The portfolio is not hedged to offset movements in the currency markets. In order to
           reduce the impact on returns from currency fluctuations the investor must hedge all currency
           exposure on a monthly basis using the currency exposure pie chart that can found in the
           publication.

           The portfolio’s returns are calculated on gross basis (excluding dividends, transaction
           cost and taxes). Net returns after taxes may vary between investors due to different tax
           treatments on dividends and capital gains depending on the tax jurisdictions. Transaction cost may
           vary between different brokers and, indeed, between clients.

           Due to the monthly rebalancing of the portfolio monthly transaction costs of 0.25 percent
           are higher than for a traditional buy and hold portfolio. Based on a sample test the portfolio‟s
           monthly dividend return of around 0.5 percent compensates for the above monthly average
           transaction costs estimated to be around 0.25 percent. The back-test‟s positive risk-adjusted results
           are excluding dividend and transaction costs which would normally give rise to concerns about
           alpha when correcting for transaction costs. However, our sample tests on the back-testing period
           show that dividends offset the transaction costs.

           The new portfolio. The Global Value Equity Portfolio portfolio is an update of the original portfolio
           we released in September 2010. In further testing we found that by changing the parameter
           settings we could receive a better risk adjusted return. Furthermore, we now have monthly holding
           periods creating a composite index.


Research methodology
           Saxo Bank’s Global Value Equity Strategy portfolio is designed to address the classic
           challenge in equity portfolio research: how to produce excess return given a benchmark
           index. The aim, therefore, is to create a portfolio that generates a positive Sharpe Ratio indicating
           the portfolio produced excess return over the risk-free rate for each unit of risk taken.

           According to the existing literature in the field it is possible, using various value criteria,
           to create a portfolio that outperforms the chosen benchmark index on a risk-adjusted
           basis. Studies such as Fama and French (1992), Lakonishok, Shleifer and Vishny (1994) and
           Piotroski (2002)1 document that significant excess return is possible for high book-to-market
           portfolios (that is a portfolio with a low price-to-book ratio). Following this line of research our
           portfolio uses Benjamin Graham deep value criteria (published by Rea in a Journal of Portfolio
           Management article from 1977)2, amongst other criteria, such as: a trailing earnings yield (more

           1
             Eugene F. Fama and Kenneth R. French (1992), The Cross-Section of Expected Returns, The Journal of Finance, vol. XLVII, no.
           2, pp. 427-465; Josef Lakonishok, Andrei Shleifer and Robert W. Vishny (1994), Contrarian Investment, Extrapolation, and Risk,
           The Journal of Finance, vol. 49, no. 5, pp. 1541-1578; Joseph D. Piotroski (2002), Value Investing: The Use of Historical
           Financial Statement Information to Separate Winners from Losers, The University of Chigago School of Business.
           2
             James B. Rea (1977), Remembering Benjamin Graham – Teacher and Friend, Journal of Portfolio Management, vol. 3, no. 4,
           pp. 66-72.
                                                                                                                                       5
February 01, 2011




          specifically CAPE3) greater than twice the corporate bond yield, a dividend yield at least equal to
          two-thirds of the corporate AAA bond yield and a low debt-to-equity ratio.

          The Saxo Bank Global Value Equity portfolio is constructed using a bottom-up approach
          which de-emphasises the significance of economic and market cycles. On this basis, the
          portfolio will be fully-invested at all times. One of the consequences of being invested at all
          times is downward pressure on the portfolio‟s alpha while creating a higher beta. The latter
          argument is not that intuitive because value stocks are typically perceived as producing stable
          returns (low beta and positive alpha). This is mitigated because we are using deep value criteria
          that will increase the number of companies with depressed valuations, which will lead to higher
          volatility (beta). Note, higher volatility does not necessarily mean higher risk (as in underlying
          business risk). Our hypothesis is the portfolio will compensate on a risk-adjusted basis for our risk-
          taking in these depressed and neglected companies measured as low P/B stocks.

          Our monthly stock sample is selected according to our search criteria and the universe is
          cash equities available to trade on the Saxo Bank trading platforms 4. We also limit the
          universe to primary issues (listings), but include inactive stocks to ensure the population does not
          include survivorship bias from excluding bankruptcies, mergers and delisting etc. The difference
          between active and inactive population of stocks is 19,490 and 37,301 irrespectively.

          Our research design is based on a few screening criteria such as market value, average
          daily trading volume, cyclical adjusted price earnings (CAPE), dividend yield and interest-
          bearing debt over equity. To generate a portfolio with medium-to-low business and liquidity risk
          only stocks (and companies) with a market capitalisation above USD 1 billion (as of 2010
          approximately 2,460 companies pass this criterion) and 60-day average daily trading volume above
          EUR 1.5 million are permitted. The CAPE 3-year parameter is set to maximum of 16 which equals a
          minimum earnings yield of 6.25%. This constraint limits the sample to stocks with conservative
          valuations. The dividend yield should at least equal two-thirds of the corporate AAA bond yield
          which on average through the back-testing period is a minimum of 3.3%. Interest-bearing debt
          should be less than two-thirds of equity excluding highly leverage companies. Benjamin Graham
          preferred stocks with P/B ratios below two which we are also applying in our.

          The first iteration of the portfolio was built on a trailing earnings (CAPE 7-year) yield
          greater than twice the corporate AAA bond yield. However, this limited our sample too
          much (sometimes only five stocks passed our screening in a single month). Thus we
          changed the parameter to CAPE 3-year below 16 to increase the monthly sample. The problem
          presented was that a relatively high stable corporate AAA bond yields around five percent, which in
          return equals an earnings yield of at least 10%. For this to be met CAPE 7-year would have to be
          below 10, which is virtually impossible to obtain for long periods in the equity market – we would
          not be able to be invested at all times in the equity market.


Back-testing methodology
          We set the last day of the prior month as our back-testing date. For example when back-
          testing January 2006 we use the back-testing date of 31 December 2005. Each monthly screening
          provides the stocks that pass our criteria and returns all relevant parameter data. The start back
          test date is set at 31 December 2004, which means that the portfolio‟s beginning date is 1 January
          2005. This provides us with 70 monthly return observations which are sufficient enough to generate
          valid statistical analyses such as beta, alpha, Sharpe ratio and Treynor measures.


          3
            CAPE is the current market price divided with a chosen period of earnings per share (EPS) and the concept was first published
          and used by Benjamin Graham and David Dodd in their book Security Analysis (1934). They emphasised using no less than five
          years of annual EPS. The concept is based on adjusting the EPS for cyclical upward or downward extremes (smoothing out the
          earnings pattern). Through our iterative research we observed that our mix of value criteria produced a too narrow a sample to
          conduct a diversified portfolio in some early observation (particularly in 2005). From a sensitivity analysis of our parameters the
          CAPE parameter came out as the most sensitive. On this basis we concluded to change our CAPE parameter from originally CAPE
          7 yr. (current market price divided with the latest seven years of annual EPS) to CAPE 3 yr. We will use CAPE and CAPE 3 yr.
          interchangeably in this paper.
          4
            See appendix for the stock exchanges on which Saxo Bank facilitates cash equity trading.
                                                                                                                                           6
February 01, 2011




In order to avoid having look-ahead bias in our portfolio we use lagging arguments on all
relevant parameters in the portfolio. Our data provider does not have a point-in-time database
on fundamental data, meaning that if our back-testing date is 31 January 2006 and we are looking
back on the last annual report data, we receive annual report data from 2005 instead of 2004
despite the information first being available to the public in February or March 2005. By
implementing three month lagging arguments on all relevant parameters, we avoid having look-
ahead bias in our portfolio.

Each month the screening output is analysed and the stocks are ranked based on a
weighted average of separate rankings for Piotroski score, CAPE and P/B. The 20 stocks
with the lowest weighted ranking (most attractive valuation and Piotroski score) are selected as the
forthcoming month‟s portfolio. Based on the monthly price return adjusted to currency cross
changes in EUR we calculate the portfolio‟s equally weighted return for that month.

The portfolio is rebalanced every month, thus the holding period is dynamic in the sense
that a stock will be re-elected to our portfolio if it still is among the 20 most promising
stocks in terms of valuation and Piotroski score. A stock that increases far more in price
relative to other value stocks will probably have a short holding period. If the potential price
appreciation has not materialised yet the stock will usually remain in the portfolio.

In back-testing, our portfolio would have produced an annual gross return, excluding
dividends (monthly dividends are estimated to be 0.5 percent) and transaction costs
(monthly costs estimated to be 0.25 percent), of 10.7% compared to 0.4% for MSCI
World Index EUR. See our comments about transaction costs under „Portfolio basics‟. Even though
our weighted holding period is shorter compared to the normal value philosophy the total return
compensates for the additional costs related to our monthly rebalancing. Our portfolio produced
excess return over the MSCI World Index EUR in 40 out of 70 months. This corresponds to around
57.1% positive excess return observations throughout the back-testing period.

We calculate the Sharpe ratio, beta, alpha, R2 and correlation based on monthly return
observations for the portfolio and MSCI World Index EUR. We use the iBoxx EUR Treasuries
1-3Y Total Return Index as our risk-free rate. Beta and alpha are calculated with linear regression of
the portfolio‟s and MSCI World Index EUR‟s monthly excess return over the risk-free rate. The
portfolio performed well over the back-testing period with a positive Sharpe Ratio of 0.08 (on a
monthly basis), beta of 1.38 and alpha of 0.01 with R2 of 80.9% and correlation between monthly
return of the portfolio and MSCI World Index EUR of 81.8%.

The portfolio’s return distribution over the back-testing period has had a positive
skewness and excess kurtosis. Our portfolio has a positive skewness of 0.06 indicating that the
return distribution has an asymmetric tail extending towards more positive values. But the value
lies within one standard deviation and thus the value is probably just a chance fluctuation from zero
– that is the return distribution is probably symmetric. Our portfolio has an excess kurtosis of 4.33
which means that the returns follow a leptokurtic distribution (more peaked values). Our portfolio‟s
kurtosis lies above two standard deviations indicating that our portfolio has significantly peaked
return distribution which point towards it having fat tails (higher probabilities of larger positive and
negative monthly returns). Thus we should expect large positive as well as negative returns.
Historical data also suggests the maximum monthly return since 2005 has been 27.5% for the
portfolio compared to 11.1% for MSCI World Index EUR5.

5
  This publication refers to past performance. Past performance is not a reliable indicator of future performance. Indications of
past performance displayed on this publication will not necessarily be repeated in the future. No representation is being made
that any investment will or is likely to achieve profits or losses similar to those achieved in the past or that significant losses will
be avoided.
Statements contained on this publication that are not historical facts and which may be simulated past performance or future
performance data are based on current expectations, estimates, projections, opinions and beliefs of the Saxo Bank Group. Such
statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon.
Additionally, this publication may contain 'forward-looking statements'. Actual events or results or actual performance may differ
materially from those reflected or contemplated in such forward-looking statements.

                                                                                                                                      7
February 01, 2011




             Appendix - stock exchanges available for trading (cash
             equity)

   American Stock Exchange

   Euronext Amsterdam

   Australian Stock Exchange Ltd.

   Euronext Brussels

   OMX Copenhagen

   OMX Copenhagen – First North

   Hong Kong Stock Exchange

   OMX Helsinki

   Euronext Lisbon

   London International Exchange

   London Stock Exchange SEAQ Market

   London Stock Exchange SETS Market

   Milano Stock Exchange

   NASDAQ Global Markets

   NASDAQ Capital Markets

   New York Stock Exchange

   NYSE ARCA

   Oslo Stock Exchange

   OTC Bulletin Board on NASDAQ

   Euronext Paris

   Singapore Exchange Securities Trading Limited

   Sistema De Interconexion Bursatil Espanol

   OMX Stockholm

   OMX Stockholm – First North

   Swiss Exchange

   Wiener Börse (Vienna) Stock Exchange

   SWX Europe




                                                                      8
February 01, 2011




NON-INDEPENDENT INVESTMENT RESEARCH

This investment research has not been prepared in accordance with legal requirements designed to promote the independence of
investment research. Further it is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Saxo Bank, its affiliates or staff, may perform services for, solicit business from, hold long or short positions in, or otherwise be
interested in the investments (including derivatives), of any issuer mentioned herein.

None of the information contained herein constitutes an offer (or solicitation of an offer) to buy or sell any currency, product or
financial instrument, to make any investment, or to participate in any particular trading strategy. This material is produced for
marketing and/or informational purposes only and Saxo Bank A/S and its owners, subsidiaries and affiliates whether acting directly
or through branch offices (“Saxo Bank”) make no representation or warranty, and assume no liability, for the accuracy or
completeness of the information provided herein. In providing this material Saxo Bank has not taken into account any particular
recipient‟s investment objectives, special investment goals, financial situation, and specific needs and demands and nothing herein
is intended as a recommendation for any recipient to invest or divest in a particular manner and Saxo Bank assumes no liability for
any recipient sustaining a loss from trading in accordance with a perceived recommendation. All investments entail a risk and may
result in both profits and losses. In particular investments in leveraged products, such as but not limited to foreign exchange,
derivates and commodities can be very speculative and profits and losses may fluctuate both violently and rapidly. Speculative
trading is not suitable for all investors and all recipients should carefully consider their financial situation and consult financial
advisor(s) in order to understand the risks involved and ensure the suitability of their situation prior to making any investment,
divestment or entering into any transaction. Any mentioning herein, if any, of any risk may not be, and should not be considered to
be, neither a comprehensive disclosure or risks nor a comprehensive description such risks. Any expression of opinion may be
personal to the author and may not reflect the opinion of Saxo Bank and all expressions of opinion are subject to change without
notice (neither prior nor subsequent).

This publication refers to past performance. Past performance is not a reliable indicator of future performance. Indications of past
performance displayed on this publication will not necessarily be repeated in the future. No representation is being made that any
investment will or is likely to achieve profits or losses similar to those achieved in the past, or that significant losses will be
avoided.

Statements contained on this publication that are not historical facts and which may be simulated past performance or future
performance data are based on current expectations, estimates, projections, opinions and beliefs of the Saxo Bank Group. Such
statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon.
Additionally, this publication may contain 'forward-looking statements'. Actual events or results or actual performance may differ
materially from those reflected or contemplated in such forward-looking statements.

This material is confidential and should not be copied, distributed, published or reproduced in whole or in part or disclosed by
recipients to any other person.

Any information or opinions in this material are not intended for distribution to, or use by, any person in any jurisdiction or country
where such distribution or use would be lawful. The information in this document is not directed at or intended for “US Persons”
within the meaning of the United States Securities Act of 1993, as amended and the United States Securities Exchange Act of
1934, as amended.


The Saxo Bank Group is under the supervision of the Danish Financial Supervisory Authority (In Danish: "Finanstilsynet") and is
subject to the Danish Executive Order on Good Business Practice for Financial Undertakings.


Saxo Bank A/S
Philip Heymans Allé 15
2900 Hellerup
Denmark
Phone: +45 39 77 40 00
Reg. No. 1149
CVR. No. 15731249

This disclaimer is subject to Saxo Bank's Full Disclaimer available at www.saxobank.com/disclaimer.




                                                                                                                                        9

Más contenido relacionado

La actualidad más candente

Hilltop decorrelated fund october 2013 factsheet
Hilltop decorrelated fund october 2013 factsheetHilltop decorrelated fund october 2013 factsheet
Hilltop decorrelated fund october 2013 factsheet
John Robertson
 
24771 Merlon Retirement Papers_FINAL
24771 Merlon Retirement Papers_FINAL24771 Merlon Retirement Papers_FINAL
24771 Merlon Retirement Papers_FINAL
Sam Morris
 
Hilltop decorrelated fund august 2013 factsheet
Hilltop decorrelated fund august 2013 factsheetHilltop decorrelated fund august 2013 factsheet
Hilltop decorrelated fund august 2013 factsheet
John Robertson
 
John hancock-lesson
John hancock-lessonJohn hancock-lesson
John hancock-lesson
lsorrentino1
 
rathbones_charity_white_paper_absolute_vs_relative_return_investing
rathbones_charity_white_paper_absolute_vs_relative_return_investingrathbones_charity_white_paper_absolute_vs_relative_return_investing
rathbones_charity_white_paper_absolute_vs_relative_return_investing
Andrew Pitt
 

La actualidad más candente (20)

Hilltop decorrelated fund october 2013 factsheet
Hilltop decorrelated fund october 2013 factsheetHilltop decorrelated fund october 2013 factsheet
Hilltop decorrelated fund october 2013 factsheet
 
Investment portfolio presentation
Investment portfolio presentationInvestment portfolio presentation
Investment portfolio presentation
 
24771 Merlon Retirement Papers_FINAL
24771 Merlon Retirement Papers_FINAL24771 Merlon Retirement Papers_FINAL
24771 Merlon Retirement Papers_FINAL
 
Hilltop decorrelated fund august 2013 factsheet
Hilltop decorrelated fund august 2013 factsheetHilltop decorrelated fund august 2013 factsheet
Hilltop decorrelated fund august 2013 factsheet
 
Olympic Wealth Fund, 'Javelin' Fund fact sheet class 'B' February 2015
Olympic Wealth Fund, 'Javelin' Fund fact sheet class 'B' February 2015Olympic Wealth Fund, 'Javelin' Fund fact sheet class 'B' February 2015
Olympic Wealth Fund, 'Javelin' Fund fact sheet class 'B' February 2015
 
ICICI Prudential Quant Fund
ICICI Prudential Quant FundICICI Prudential Quant Fund
ICICI Prudential Quant Fund
 
IDFC Dynamic Equity Fund_FAQs
IDFC Dynamic Equity Fund_FAQsIDFC Dynamic Equity Fund_FAQs
IDFC Dynamic Equity Fund_FAQs
 
John hancock-lesson
John hancock-lessonJohn hancock-lesson
John hancock-lesson
 
DSP Focus Fund
DSP Focus FundDSP Focus Fund
DSP Focus Fund
 
Why invest in_mutual_fund - FinVise India
Why invest in_mutual_fund - FinVise IndiaWhy invest in_mutual_fund - FinVise India
Why invest in_mutual_fund - FinVise India
 
Sip ppt
Sip pptSip ppt
Sip ppt
 
rathbones_charity_white_paper_absolute_vs_relative_return_investing
rathbones_charity_white_paper_absolute_vs_relative_return_investingrathbones_charity_white_paper_absolute_vs_relative_return_investing
rathbones_charity_white_paper_absolute_vs_relative_return_investing
 
ICICI Prudential Business Cycle Fund
ICICI Prudential Business Cycle FundICICI Prudential Business Cycle Fund
ICICI Prudential Business Cycle Fund
 
Sip presentation
Sip presentationSip presentation
Sip presentation
 
SBI Dynamic Asset Allocation Fund: A Hybrid Mutual Fund Scheme - Aug 16
SBI Dynamic Asset Allocation Fund: A Hybrid Mutual Fund Scheme - Aug 16SBI Dynamic Asset Allocation Fund: A Hybrid Mutual Fund Scheme - Aug 16
SBI Dynamic Asset Allocation Fund: A Hybrid Mutual Fund Scheme - Aug 16
 
Japan_Equity_Strategy
Japan_Equity_StrategyJapan_Equity_Strategy
Japan_Equity_Strategy
 
HSBC-News30
HSBC-News30HSBC-News30
HSBC-News30
 
3 2) factsheet
3 2) factsheet3 2) factsheet
3 2) factsheet
 
BOJ_Policy
BOJ_PolicyBOJ_Policy
BOJ_Policy
 
Hdfc retirement fund
Hdfc retirement fundHdfc retirement fund
Hdfc retirement fund
 

Destacado (7)

FASES DEL DESARROLLO ELECTRÓNICO
FASES DEL DESARROLLO ELECTRÓNICOFASES DEL DESARROLLO ELECTRÓNICO
FASES DEL DESARROLLO ELECTRÓNICO
 
Inteligencia artificial
Inteligencia artificialInteligencia artificial
Inteligencia artificial
 
Real Rates Of Return On C Ds Public Xadv14975 V 04 08
Real Rates Of Return On C Ds   Public   Xadv14975 V 04 08Real Rates Of Return On C Ds   Public   Xadv14975 V 04 08
Real Rates Of Return On C Ds Public Xadv14975 V 04 08
 
M y k
M y kM y k
M y k
 
Saxo Bank Government Bonds
Saxo Bank Government BondsSaxo Bank Government Bonds
Saxo Bank Government Bonds
 
German Government Bonds/Bunds
German Government Bonds/BundsGerman Government Bonds/Bunds
German Government Bonds/Bunds
 
SEO Training 2016 Search Engine Optimization Tutorials
SEO Training 2016  Search Engine Optimization TutorialsSEO Training 2016  Search Engine Optimization Tutorials
SEO Training 2016 Search Engine Optimization Tutorials
 

Similar a Global Value Equity Portfolio - February 2011

Investment Edge Quarter 1 2011
Investment Edge Quarter 1 2011Investment Edge Quarter 1 2011
Investment Edge Quarter 1 2011
simonkbowen
 
2011 - Q1 - Commentary
2011 - Q1 - Commentary2011 - Q1 - Commentary
2011 - Q1 - Commentary
Drew Beja
 
Icm aniacs report final
Icm aniacs report finalIcm aniacs report final
Icm aniacs report final
George Cotton
 
2011 - Q1 - Commentary
2011 - Q1 - Commentary2011 - Q1 - Commentary
2011 - Q1 - Commentary
Drew Beja
 
Quarterly reports - WIOF Global Listed Utilities Fund
Quarterly reports - WIOF Global Listed Utilities FundQuarterly reports - WIOF Global Listed Utilities Fund
Quarterly reports - WIOF Global Listed Utilities Fund
Ken Teale
 

Similar a Global Value Equity Portfolio - February 2011 (20)

[DE] NN Investment Partners Global Convertible Opportunities
[DE] NN Investment Partners Global Convertible Opportunities[DE] NN Investment Partners Global Convertible Opportunities
[DE] NN Investment Partners Global Convertible Opportunities
 
[LATAM ES] Strategy Brief / Global Convertible Opportunities / November 2015
[LATAM ES] Strategy Brief / Global Convertible Opportunities / November 2015[LATAM ES] Strategy Brief / Global Convertible Opportunities / November 2015
[LATAM ES] Strategy Brief / Global Convertible Opportunities / November 2015
 
[ES] Strategy Brief / Global Convertible Opportunities / November 2015
[ES] Strategy Brief / Global Convertible Opportunities / November 2015[ES] Strategy Brief / Global Convertible Opportunities / November 2015
[ES] Strategy Brief / Global Convertible Opportunities / November 2015
 
[JP] Strtaegy Brief / Global Convertible Opportunities / December 2015
[JP] Strtaegy Brief / Global Convertible Opportunities / December 2015[JP] Strtaegy Brief / Global Convertible Opportunities / December 2015
[JP] Strtaegy Brief / Global Convertible Opportunities / December 2015
 
[UK] Strategy Brief / Global Convertible Opportunities / December 2015
[UK] Strategy Brief / Global Convertible Opportunities / December 2015[UK] Strategy Brief / Global Convertible Opportunities / December 2015
[UK] Strategy Brief / Global Convertible Opportunities / December 2015
 
[CH] Strategy Brief / Global Convertible Opportunities / December 2015
[CH] Strategy Brief / Global Convertible Opportunities / December 2015[CH] Strategy Brief / Global Convertible Opportunities / December 2015
[CH] Strategy Brief / Global Convertible Opportunities / December 2015
 
[LU] Strategy Brief / Global Convertible Opportunities / December 2015
[LU] Strategy Brief / Global Convertible Opportunities / December 2015[LU] Strategy Brief / Global Convertible Opportunities / December 2015
[LU] Strategy Brief / Global Convertible Opportunities / December 2015
 
[LATAM EN] Strategy Brief / Global Convertible Opportunities / December 2015
[LATAM EN] Strategy Brief /  Global Convertible Opportunities / December 2015[LATAM EN] Strategy Brief /  Global Convertible Opportunities / December 2015
[LATAM EN] Strategy Brief / Global Convertible Opportunities / December 2015
 
[EN] Strategy Brief / Global Convertible Opportunities / December 2015
[EN] Strategy Brief / Global Convertible Opportunities / December 2015[EN] Strategy Brief / Global Convertible Opportunities / December 2015
[EN] Strategy Brief / Global Convertible Opportunities / December 2015
 
Investment Edge Quarter 1 2011
Investment Edge Quarter 1 2011Investment Edge Quarter 1 2011
Investment Edge Quarter 1 2011
 
2011 - Q1 - Commentary
2011 - Q1 - Commentary2011 - Q1 - Commentary
2011 - Q1 - Commentary
 
Olympic Wealth Fund Javelin fund fact sheet class 'A' December end
Olympic Wealth Fund Javelin fund fact sheet class 'A' December endOlympic Wealth Fund Javelin fund fact sheet class 'A' December end
Olympic Wealth Fund Javelin fund fact sheet class 'A' December end
 
Alhuda CIBE - RIETs International Allocation Views
Alhuda CIBE - RIETs International Allocation ViewsAlhuda CIBE - RIETs International Allocation Views
Alhuda CIBE - RIETs International Allocation Views
 
SP Capital IQ European Insurers
SP Capital IQ European InsurersSP Capital IQ European Insurers
SP Capital IQ European Insurers
 
Icm aniacs report final
Icm aniacs report finalIcm aniacs report final
Icm aniacs report final
 
2011 - Q1 - Commentary
2011 - Q1 - Commentary2011 - Q1 - Commentary
2011 - Q1 - Commentary
 
Quarterly reports - WIOF Global Listed Utilities Fund
Quarterly reports - WIOF Global Listed Utilities FundQuarterly reports - WIOF Global Listed Utilities Fund
Quarterly reports - WIOF Global Listed Utilities Fund
 
LBS Asset Allocation - January Update
LBS Asset Allocation - January UpdateLBS Asset Allocation - January Update
LBS Asset Allocation - January Update
 
2Q09 Asset Allocation
2Q09 Asset Allocation2Q09 Asset Allocation
2Q09 Asset Allocation
 
Olympic Wealth Fund Marathon Class 'A' April Fact sheet
Olympic Wealth Fund Marathon Class 'A' April Fact sheetOlympic Wealth Fund Marathon Class 'A' April Fact sheet
Olympic Wealth Fund Marathon Class 'A' April Fact sheet
 

Más de Trading Floor

Más de Trading Floor (20)

Saxo Bank Corporate Bonds
Saxo Bank Corporate BondsSaxo Bank Corporate Bonds
Saxo Bank Corporate Bonds
 
Saxo Bank Emerging Markets Bonds
Saxo Bank Emerging Markets BondsSaxo Bank Emerging Markets Bonds
Saxo Bank Emerging Markets Bonds
 
Saxo Fundamental FX Portfolio for March 2011
Saxo Fundamental FX Portfolio for March 2011Saxo Fundamental FX Portfolio for March 2011
Saxo Fundamental FX Portfolio for March 2011
 
Earnings Releases 7.March - 13.March 2011
Earnings Releases 7.March - 13.March 2011 Earnings Releases 7.March - 13.March 2011
Earnings Releases 7.March - 13.March 2011
 
Dynamic weights
Dynamic weightsDynamic weights
Dynamic weights
 
FOREX - TECHNICAL ANALYSIS: FIBONACCI (4.2)
FOREX - TECHNICAL ANALYSIS: FIBONACCI (4.2)FOREX - TECHNICAL ANALYSIS: FIBONACCI (4.2)
FOREX - TECHNICAL ANALYSIS: FIBONACCI (4.2)
 
FOREX - TRADING PSYCHOLOGY (3.3)
FOREX - TRADING PSYCHOLOGY (3.3)FOREX - TRADING PSYCHOLOGY (3.3)
FOREX - TRADING PSYCHOLOGY (3.3)
 
FOREX - TECHNICAL ANALYSIS: PRICE PATTERNS (3.2)
FOREX - TECHNICAL ANALYSIS: PRICE PATTERNS (3.2)FOREX - TECHNICAL ANALYSIS: PRICE PATTERNS (3.2)
FOREX - TECHNICAL ANALYSIS: PRICE PATTERNS (3.2)
 
FOREX - TECHNICAL ANALYSIS: TRENDS, SUPPORT AND RESISTANCE (1.4)
FOREX - TECHNICAL ANALYSIS: TRENDS, SUPPORT AND RESISTANCE (1.4)FOREX - TECHNICAL ANALYSIS: TRENDS, SUPPORT AND RESISTANCE (1.4)
FOREX - TECHNICAL ANALYSIS: TRENDS, SUPPORT AND RESISTANCE (1.4)
 
FOREX - FUNDAMENTALS MAKE CURRENCY PAIRS MOVE (1.3)
FOREX - FUNDAMENTALS MAKE CURRENCY PAIRS MOVE (1.3)FOREX - FUNDAMENTALS MAKE CURRENCY PAIRS MOVE (1.3)
FOREX - FUNDAMENTALS MAKE CURRENCY PAIRS MOVE (1.3)
 
FOREX - CURRENCIES COME IN PAIRS (1.2)
FOREX - CURRENCIES COME IN PAIRS (1.2)FOREX - CURRENCIES COME IN PAIRS (1.2)
FOREX - CURRENCIES COME IN PAIRS (1.2)
 
Earnings Releases 21.February - 27. February 2011
Earnings Releases 21.February - 27. February 2011Earnings Releases 21.February - 27. February 2011
Earnings Releases 21.February - 27. February 2011
 
Commodities on the radar - Weekly Commodity Update 1.2.11
Commodities on the radar - Weekly Commodity Update 1.2.11Commodities on the radar - Weekly Commodity Update 1.2.11
Commodities on the radar - Weekly Commodity Update 1.2.11
 
Earnings releases 7. February - 11.February 2011
Earnings releases  7. February - 11.February 2011Earnings releases  7. February - 11.February 2011
Earnings releases 7. February - 11.February 2011
 
Earnings releases 2.February - 11.February 2011
Earnings releases 2.February - 11.February 2011Earnings releases 2.February - 11.February 2011
Earnings releases 2.February - 11.February 2011
 
Earnings releases 17. January - 23. January 2011
Earnings releases 17. January - 23. January 2011Earnings releases 17. January - 23. January 2011
Earnings releases 17. January - 23. January 2011
 
Forex Portfolio for February 2011
Forex Portfolio for February 2011Forex Portfolio for February 2011
Forex Portfolio for February 2011
 
Forex Portfolio for January 2011
Forex Portfolio for January 2011Forex Portfolio for January 2011
Forex Portfolio for January 2011
 
Saxo Asset Allocation for February 2011
Saxo Asset Allocation for February 2011Saxo Asset Allocation for February 2011
Saxo Asset Allocation for February 2011
 
Monthly Forex Update by Saxo Bank
Monthly Forex Update by Saxo BankMonthly Forex Update by Saxo Bank
Monthly Forex Update by Saxo Bank
 

Último

+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...
+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...
+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...
Health
 
Abortion pills in Saudi Arabia (+919707899604)cytotec pills in dammam
Abortion pills in Saudi Arabia (+919707899604)cytotec pills in dammamAbortion pills in Saudi Arabia (+919707899604)cytotec pills in dammam
Abortion pills in Saudi Arabia (+919707899604)cytotec pills in dammam
samsungultra782445
 
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdfMASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
Cocity Enterprises
 
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdfFOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
Cocity Enterprises
 
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadhabortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
samsungultra782445
 

Último (20)

Famous Kala Jadu, Kala ilam specialist in USA and Bangali Amil baba in Saudi ...
Famous Kala Jadu, Kala ilam specialist in USA and Bangali Amil baba in Saudi ...Famous Kala Jadu, Kala ilam specialist in USA and Bangali Amil baba in Saudi ...
Famous Kala Jadu, Kala ilam specialist in USA and Bangali Amil baba in Saudi ...
 
+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...
+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...
+971565801893>>SAFE ORIGINAL ABORTION PILLS FOR SALE IN DUBAI,RAK CITY,ABUDHA...
 
FE Credit and SMBC Acquisition Case Studies
FE Credit and SMBC Acquisition Case StudiesFE Credit and SMBC Acquisition Case Studies
FE Credit and SMBC Acquisition Case Studies
 
In Sharjah ௵(+971)558539980 *_௵abortion pills now available.
In Sharjah ௵(+971)558539980 *_௵abortion pills now available.In Sharjah ௵(+971)558539980 *_௵abortion pills now available.
In Sharjah ௵(+971)558539980 *_௵abortion pills now available.
 
Abortion pills in Saudi Arabia (+919707899604)cytotec pills in dammam
Abortion pills in Saudi Arabia (+919707899604)cytotec pills in dammamAbortion pills in Saudi Arabia (+919707899604)cytotec pills in dammam
Abortion pills in Saudi Arabia (+919707899604)cytotec pills in dammam
 
Explore Dual Citizenship in Africa | Citizenship Benefits & Requirements
Explore Dual Citizenship in Africa | Citizenship Benefits & RequirementsExplore Dual Citizenship in Africa | Citizenship Benefits & Requirements
Explore Dual Citizenship in Africa | Citizenship Benefits & Requirements
 
Collecting banker, Capacity of collecting Banker, conditions under section 13...
Collecting banker, Capacity of collecting Banker, conditions under section 13...Collecting banker, Capacity of collecting Banker, conditions under section 13...
Collecting banker, Capacity of collecting Banker, conditions under section 13...
 
Test bank for advanced assessment interpreting findings and formulating diffe...
Test bank for advanced assessment interpreting findings and formulating diffe...Test bank for advanced assessment interpreting findings and formulating diffe...
Test bank for advanced assessment interpreting findings and formulating diffe...
 
Q1 2024 Conference Call Presentation vF.pdf
Q1 2024 Conference Call Presentation vF.pdfQ1 2024 Conference Call Presentation vF.pdf
Q1 2024 Conference Call Presentation vF.pdf
 
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdfMASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
 
劳伦森大学毕业证
劳伦森大学毕业证劳伦森大学毕业证
劳伦森大学毕业证
 
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdfFOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
 
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadhabortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
 
Responsible Finance Principles and Implication
Responsible Finance Principles and ImplicationResponsible Finance Principles and Implication
Responsible Finance Principles and Implication
 
Strategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate PresentationStrategic Resources May 2024 Corporate Presentation
Strategic Resources May 2024 Corporate Presentation
 
Webinar on E-Invoicing for Fintech Belgium
Webinar on E-Invoicing for Fintech BelgiumWebinar on E-Invoicing for Fintech Belgium
Webinar on E-Invoicing for Fintech Belgium
 
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdf
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdfSeeman_Fiintouch_LLP_Newsletter_May-2024.pdf
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdf
 
Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...
Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...
Certified Kala Jadu, Black magic specialist in Rawalpindi and Bangali Amil ba...
 
Female Escorts Service in Hyderabad Starting with 5000/- for Savita Escorts S...
Female Escorts Service in Hyderabad Starting with 5000/- for Savita Escorts S...Female Escorts Service in Hyderabad Starting with 5000/- for Savita Escorts S...
Female Escorts Service in Hyderabad Starting with 5000/- for Savita Escorts S...
 
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budgetCall Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
 

Global Value Equity Portfolio - February 2011

  • 1. February 01, 2011 A strong January; 5.4 percent excess return Christian Blaabjerg The Global Value Equity portfolio performed strongly in January with Chief Equity Strategist most contribution coming from our stock selection, driven by CNP ctb@saxobank.com Assurances and Almirall, with almost no help from our sector allocation. +45 3977 4669  The Saxo Bank Global Value Equity Portfolio would have made Peter Garnry excess return of 3.4 percent1 in the three months since the actual Equity Strategist inception in November 2010. In January, the portfolio returned 5.4 pg@saxobank.com percent compared to the 0.01 percent for the MSCI World EUR index. +45 3977 6786  Almirall, the Spanish pharmaceutical company, is, despite the 24 percent surge in January still a likely takeover candidate. The extraordinary surge was driven by positive results from ATTAIN phase III study. We have been saying for several months that Almirall is a takeover candidate and in January Leerink Swann, a premier US investment bank focused on healthcare, said AstraZeneca may consider buying Forrest Laboratories or Almirall due to their attractive late-stage pipelines.  We are still very bullish on insurance stocks and believe our exposure will drive outperformance over the next quarters. Among insurance stocks we prefer CNP Assurances (still our most bullish individual case), Tryg, Catlin Group and Scor - all trading at attractive levels compared to their earnings power and prospects. 1. Past performance disclaimer This publication refers to past performance. Past performance is not a reliable indicator of future performance. Indications of past performance displayed on this publication will not necessarily be repeated in the future. No representation is being made that any investment will or is likely to achieve profits or losses similar to those achieved in the past or that significant losses will be avoided. Statements contained on this publication that are not historical facts and which may be simulated past performance or future performance data are based on current expectations, estimates, projections, opinions and beliefs of the Saxo Bank Group. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this publication may contain 'forward- looking statements'. Actual events or results or actual performance may differ materially from those reflected or contemplated in such forward-looking statements.
  • 2. February 01, 2011 Global Value Equity Portfolio – February 2011 Changes to the February portfolio Only one stock placed on the bench despite a strong showing from many constituents Helvetia Holding returned 3.46 percent in January and its relative valuation has benched the stock for now. It helped the portfolio outperform as the benchmark only returned 0.01 percent in January. That was despite it being downgraded to “underperform” by Credit Suisse. So, which stock is in for February? CapitaCommerical Trust, a property trust company located in Singapore, is the new kid on the block following a 4.7 percent decline in January adding to its relative valuation. The company is currently valued at CAPE ratio (price over average three years earnings per share) of 9.42 and a price-to-book of 1.2. During January UBS maintained its “buy” recommendation on the stock and on current levels we think it could add 10-20 percent in gains before losing its relative valuation attractiveness. Our February portfolio is comprised of the following stocks: 2
  • 3. February 01, 2011 The portfolio is still highly overweight financials stocks. Financials, particularly insurance stocks, are still trading at attractive levels relative to their earnings power over a normal economic cycle and we expect our insurance stocks to perform well over the next quarter. The portfolio’s currency exposure is primarily in EUR, GBP and HKD (75 percent). The main currency exposure is unchanged from last month with high concentration in EUR, GBP and HKD. As Helvetia Holding left our portfolio and CapitaCommerical Trust replaced it, we changed a minor five percent exposure from CHF to SGD. 3
  • 4. February 01, 2011 Global Value Equity Portfolio – January 2011 In January the portfolio returned 5.42 percent compared to 0.01 percent for MSCI World EUR index. Since inception in November 2010 the portfolio is up 11.9 percent compared to 8.5 percent for the MSCI World EUR index which corresponds to a 3.4 percentage point outperformance in three months. Which stocks were strong performers in the portfolio? Almirall, the Spanish pharmaceutical company, surged 24.0 percent in January following positive results from its‟ ATTAIN phase III study which the company develops in cooperation with Forrest Laboratories. The company is still valued attractively compared to its earnings power and late-stage pipeline making it an obvious takeover candidate for another pharmaceutical company with trouble in its pipeline. CNP Assurances, the French life insurance company, rose 19.2 percent in January on no significant public announcement but was raised to “outperform” and “overweight” from Credit Suisse and HSBC respectively. Their target price range is around EUR 19.50-20 which is a 21.1-24.2 percent premium from January‟s closing price. Kowloon Development, the Hong Kong based developer of properties, put on 17.8 percent in January on increased risk appetite for Asian real estate exposure. Which stocks held the portfolio back? Ten Network Holdings, the Australian operator of commercial television stations, declined 5.8 percent in January on no public news or events; actually it was upgraded by RBS. We see minor upside in this stock compared to the rest of the portfolio. Amlin, the U.K. insurance and reinsurance company, declined 4.2 percent in January due to a profit warning following a revision of the estimated costs from the earthquake in New Zealand; the costs doubled from first anticipated by management. January portfolio performance Performance attribution 4
  • 5. February 01, 2011 Portfolio basics Value creates excess risk-adjusted return. This equity portfolio is based on classical deep value criteria mixed with a quality indicator based on a Piotroski score. Our portfolio would have produced excess risk-adjusted return in the back testing period of 10.3%; the annual return was 10.7% p.a. compared to 0.4% p.a. return for our benchmark, the MSCI World Index EUR. Global portfolio without constrains. Our equity portfolio has no constraints in terms of exposure restrictions towards geography or sectors. The portfolio seeks to exploit deep value opportunities wherever they are located in the world. We have found during back-testing that the additional risk taken by this approach is sufficiently offset by the extra return received. Equal weighted portfolio. The portfolio is based on an equal weighted approach and the monthly return is calculated accordingly on these weights. The portfolio is not hedged to offset movements in the currency markets. In order to reduce the impact on returns from currency fluctuations the investor must hedge all currency exposure on a monthly basis using the currency exposure pie chart that can found in the publication. The portfolio’s returns are calculated on gross basis (excluding dividends, transaction cost and taxes). Net returns after taxes may vary between investors due to different tax treatments on dividends and capital gains depending on the tax jurisdictions. Transaction cost may vary between different brokers and, indeed, between clients. Due to the monthly rebalancing of the portfolio monthly transaction costs of 0.25 percent are higher than for a traditional buy and hold portfolio. Based on a sample test the portfolio‟s monthly dividend return of around 0.5 percent compensates for the above monthly average transaction costs estimated to be around 0.25 percent. The back-test‟s positive risk-adjusted results are excluding dividend and transaction costs which would normally give rise to concerns about alpha when correcting for transaction costs. However, our sample tests on the back-testing period show that dividends offset the transaction costs. The new portfolio. The Global Value Equity Portfolio portfolio is an update of the original portfolio we released in September 2010. In further testing we found that by changing the parameter settings we could receive a better risk adjusted return. Furthermore, we now have monthly holding periods creating a composite index. Research methodology Saxo Bank’s Global Value Equity Strategy portfolio is designed to address the classic challenge in equity portfolio research: how to produce excess return given a benchmark index. The aim, therefore, is to create a portfolio that generates a positive Sharpe Ratio indicating the portfolio produced excess return over the risk-free rate for each unit of risk taken. According to the existing literature in the field it is possible, using various value criteria, to create a portfolio that outperforms the chosen benchmark index on a risk-adjusted basis. Studies such as Fama and French (1992), Lakonishok, Shleifer and Vishny (1994) and Piotroski (2002)1 document that significant excess return is possible for high book-to-market portfolios (that is a portfolio with a low price-to-book ratio). Following this line of research our portfolio uses Benjamin Graham deep value criteria (published by Rea in a Journal of Portfolio Management article from 1977)2, amongst other criteria, such as: a trailing earnings yield (more 1 Eugene F. Fama and Kenneth R. French (1992), The Cross-Section of Expected Returns, The Journal of Finance, vol. XLVII, no. 2, pp. 427-465; Josef Lakonishok, Andrei Shleifer and Robert W. Vishny (1994), Contrarian Investment, Extrapolation, and Risk, The Journal of Finance, vol. 49, no. 5, pp. 1541-1578; Joseph D. Piotroski (2002), Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers, The University of Chigago School of Business. 2 James B. Rea (1977), Remembering Benjamin Graham – Teacher and Friend, Journal of Portfolio Management, vol. 3, no. 4, pp. 66-72. 5
  • 6. February 01, 2011 specifically CAPE3) greater than twice the corporate bond yield, a dividend yield at least equal to two-thirds of the corporate AAA bond yield and a low debt-to-equity ratio. The Saxo Bank Global Value Equity portfolio is constructed using a bottom-up approach which de-emphasises the significance of economic and market cycles. On this basis, the portfolio will be fully-invested at all times. One of the consequences of being invested at all times is downward pressure on the portfolio‟s alpha while creating a higher beta. The latter argument is not that intuitive because value stocks are typically perceived as producing stable returns (low beta and positive alpha). This is mitigated because we are using deep value criteria that will increase the number of companies with depressed valuations, which will lead to higher volatility (beta). Note, higher volatility does not necessarily mean higher risk (as in underlying business risk). Our hypothesis is the portfolio will compensate on a risk-adjusted basis for our risk- taking in these depressed and neglected companies measured as low P/B stocks. Our monthly stock sample is selected according to our search criteria and the universe is cash equities available to trade on the Saxo Bank trading platforms 4. We also limit the universe to primary issues (listings), but include inactive stocks to ensure the population does not include survivorship bias from excluding bankruptcies, mergers and delisting etc. The difference between active and inactive population of stocks is 19,490 and 37,301 irrespectively. Our research design is based on a few screening criteria such as market value, average daily trading volume, cyclical adjusted price earnings (CAPE), dividend yield and interest- bearing debt over equity. To generate a portfolio with medium-to-low business and liquidity risk only stocks (and companies) with a market capitalisation above USD 1 billion (as of 2010 approximately 2,460 companies pass this criterion) and 60-day average daily trading volume above EUR 1.5 million are permitted. The CAPE 3-year parameter is set to maximum of 16 which equals a minimum earnings yield of 6.25%. This constraint limits the sample to stocks with conservative valuations. The dividend yield should at least equal two-thirds of the corporate AAA bond yield which on average through the back-testing period is a minimum of 3.3%. Interest-bearing debt should be less than two-thirds of equity excluding highly leverage companies. Benjamin Graham preferred stocks with P/B ratios below two which we are also applying in our. The first iteration of the portfolio was built on a trailing earnings (CAPE 7-year) yield greater than twice the corporate AAA bond yield. However, this limited our sample too much (sometimes only five stocks passed our screening in a single month). Thus we changed the parameter to CAPE 3-year below 16 to increase the monthly sample. The problem presented was that a relatively high stable corporate AAA bond yields around five percent, which in return equals an earnings yield of at least 10%. For this to be met CAPE 7-year would have to be below 10, which is virtually impossible to obtain for long periods in the equity market – we would not be able to be invested at all times in the equity market. Back-testing methodology We set the last day of the prior month as our back-testing date. For example when back- testing January 2006 we use the back-testing date of 31 December 2005. Each monthly screening provides the stocks that pass our criteria and returns all relevant parameter data. The start back test date is set at 31 December 2004, which means that the portfolio‟s beginning date is 1 January 2005. This provides us with 70 monthly return observations which are sufficient enough to generate valid statistical analyses such as beta, alpha, Sharpe ratio and Treynor measures. 3 CAPE is the current market price divided with a chosen period of earnings per share (EPS) and the concept was first published and used by Benjamin Graham and David Dodd in their book Security Analysis (1934). They emphasised using no less than five years of annual EPS. The concept is based on adjusting the EPS for cyclical upward or downward extremes (smoothing out the earnings pattern). Through our iterative research we observed that our mix of value criteria produced a too narrow a sample to conduct a diversified portfolio in some early observation (particularly in 2005). From a sensitivity analysis of our parameters the CAPE parameter came out as the most sensitive. On this basis we concluded to change our CAPE parameter from originally CAPE 7 yr. (current market price divided with the latest seven years of annual EPS) to CAPE 3 yr. We will use CAPE and CAPE 3 yr. interchangeably in this paper. 4 See appendix for the stock exchanges on which Saxo Bank facilitates cash equity trading. 6
  • 7. February 01, 2011 In order to avoid having look-ahead bias in our portfolio we use lagging arguments on all relevant parameters in the portfolio. Our data provider does not have a point-in-time database on fundamental data, meaning that if our back-testing date is 31 January 2006 and we are looking back on the last annual report data, we receive annual report data from 2005 instead of 2004 despite the information first being available to the public in February or March 2005. By implementing three month lagging arguments on all relevant parameters, we avoid having look- ahead bias in our portfolio. Each month the screening output is analysed and the stocks are ranked based on a weighted average of separate rankings for Piotroski score, CAPE and P/B. The 20 stocks with the lowest weighted ranking (most attractive valuation and Piotroski score) are selected as the forthcoming month‟s portfolio. Based on the monthly price return adjusted to currency cross changes in EUR we calculate the portfolio‟s equally weighted return for that month. The portfolio is rebalanced every month, thus the holding period is dynamic in the sense that a stock will be re-elected to our portfolio if it still is among the 20 most promising stocks in terms of valuation and Piotroski score. A stock that increases far more in price relative to other value stocks will probably have a short holding period. If the potential price appreciation has not materialised yet the stock will usually remain in the portfolio. In back-testing, our portfolio would have produced an annual gross return, excluding dividends (monthly dividends are estimated to be 0.5 percent) and transaction costs (monthly costs estimated to be 0.25 percent), of 10.7% compared to 0.4% for MSCI World Index EUR. See our comments about transaction costs under „Portfolio basics‟. Even though our weighted holding period is shorter compared to the normal value philosophy the total return compensates for the additional costs related to our monthly rebalancing. Our portfolio produced excess return over the MSCI World Index EUR in 40 out of 70 months. This corresponds to around 57.1% positive excess return observations throughout the back-testing period. We calculate the Sharpe ratio, beta, alpha, R2 and correlation based on monthly return observations for the portfolio and MSCI World Index EUR. We use the iBoxx EUR Treasuries 1-3Y Total Return Index as our risk-free rate. Beta and alpha are calculated with linear regression of the portfolio‟s and MSCI World Index EUR‟s monthly excess return over the risk-free rate. The portfolio performed well over the back-testing period with a positive Sharpe Ratio of 0.08 (on a monthly basis), beta of 1.38 and alpha of 0.01 with R2 of 80.9% and correlation between monthly return of the portfolio and MSCI World Index EUR of 81.8%. The portfolio’s return distribution over the back-testing period has had a positive skewness and excess kurtosis. Our portfolio has a positive skewness of 0.06 indicating that the return distribution has an asymmetric tail extending towards more positive values. But the value lies within one standard deviation and thus the value is probably just a chance fluctuation from zero – that is the return distribution is probably symmetric. Our portfolio has an excess kurtosis of 4.33 which means that the returns follow a leptokurtic distribution (more peaked values). Our portfolio‟s kurtosis lies above two standard deviations indicating that our portfolio has significantly peaked return distribution which point towards it having fat tails (higher probabilities of larger positive and negative monthly returns). Thus we should expect large positive as well as negative returns. Historical data also suggests the maximum monthly return since 2005 has been 27.5% for the portfolio compared to 11.1% for MSCI World Index EUR5. 5 This publication refers to past performance. Past performance is not a reliable indicator of future performance. Indications of past performance displayed on this publication will not necessarily be repeated in the future. No representation is being made that any investment will or is likely to achieve profits or losses similar to those achieved in the past or that significant losses will be avoided. Statements contained on this publication that are not historical facts and which may be simulated past performance or future performance data are based on current expectations, estimates, projections, opinions and beliefs of the Saxo Bank Group. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this publication may contain 'forward-looking statements'. Actual events or results or actual performance may differ materially from those reflected or contemplated in such forward-looking statements. 7
  • 8. February 01, 2011 Appendix - stock exchanges available for trading (cash equity)  American Stock Exchange  Euronext Amsterdam  Australian Stock Exchange Ltd.  Euronext Brussels  OMX Copenhagen  OMX Copenhagen – First North  Hong Kong Stock Exchange  OMX Helsinki  Euronext Lisbon  London International Exchange  London Stock Exchange SEAQ Market  London Stock Exchange SETS Market  Milano Stock Exchange  NASDAQ Global Markets  NASDAQ Capital Markets  New York Stock Exchange  NYSE ARCA  Oslo Stock Exchange  OTC Bulletin Board on NASDAQ  Euronext Paris  Singapore Exchange Securities Trading Limited  Sistema De Interconexion Bursatil Espanol  OMX Stockholm  OMX Stockholm – First North  Swiss Exchange  Wiener Börse (Vienna) Stock Exchange  SWX Europe 8
  • 9. February 01, 2011 NON-INDEPENDENT INVESTMENT RESEARCH This investment research has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Further it is not subject to any prohibition on dealing ahead of the dissemination of investment research. Saxo Bank, its affiliates or staff, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives), of any issuer mentioned herein. None of the information contained herein constitutes an offer (or solicitation of an offer) to buy or sell any currency, product or financial instrument, to make any investment, or to participate in any particular trading strategy. This material is produced for marketing and/or informational purposes only and Saxo Bank A/S and its owners, subsidiaries and affiliates whether acting directly or through branch offices (“Saxo Bank”) make no representation or warranty, and assume no liability, for the accuracy or completeness of the information provided herein. In providing this material Saxo Bank has not taken into account any particular recipient‟s investment objectives, special investment goals, financial situation, and specific needs and demands and nothing herein is intended as a recommendation for any recipient to invest or divest in a particular manner and Saxo Bank assumes no liability for any recipient sustaining a loss from trading in accordance with a perceived recommendation. All investments entail a risk and may result in both profits and losses. In particular investments in leveraged products, such as but not limited to foreign exchange, derivates and commodities can be very speculative and profits and losses may fluctuate both violently and rapidly. Speculative trading is not suitable for all investors and all recipients should carefully consider their financial situation and consult financial advisor(s) in order to understand the risks involved and ensure the suitability of their situation prior to making any investment, divestment or entering into any transaction. Any mentioning herein, if any, of any risk may not be, and should not be considered to be, neither a comprehensive disclosure or risks nor a comprehensive description such risks. Any expression of opinion may be personal to the author and may not reflect the opinion of Saxo Bank and all expressions of opinion are subject to change without notice (neither prior nor subsequent). This publication refers to past performance. Past performance is not a reliable indicator of future performance. Indications of past performance displayed on this publication will not necessarily be repeated in the future. No representation is being made that any investment will or is likely to achieve profits or losses similar to those achieved in the past, or that significant losses will be avoided. Statements contained on this publication that are not historical facts and which may be simulated past performance or future performance data are based on current expectations, estimates, projections, opinions and beliefs of the Saxo Bank Group. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this publication may contain 'forward-looking statements'. Actual events or results or actual performance may differ materially from those reflected or contemplated in such forward-looking statements. This material is confidential and should not be copied, distributed, published or reproduced in whole or in part or disclosed by recipients to any other person. Any information or opinions in this material are not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be lawful. The information in this document is not directed at or intended for “US Persons” within the meaning of the United States Securities Act of 1993, as amended and the United States Securities Exchange Act of 1934, as amended. The Saxo Bank Group is under the supervision of the Danish Financial Supervisory Authority (In Danish: "Finanstilsynet") and is subject to the Danish Executive Order on Good Business Practice for Financial Undertakings. Saxo Bank A/S Philip Heymans Allé 15 2900 Hellerup Denmark Phone: +45 39 77 40 00 Reg. No. 1149 CVR. No. 15731249 This disclaimer is subject to Saxo Bank's Full Disclaimer available at www.saxobank.com/disclaimer. 9